Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Opioid-Related Disorders 1Lymphoma, Follicular 1

Interventions

Fluticasone-Salmeterol Drug Combination 2Fluticasone 2Diclofenac 2ziconotide 1secukinumab 1ropinirole 1aliskiren 1acetaminophen, codeine drug combination 1Venlafaxine Hydrochloride 1Thiotepa 1Tacrolimus 1Sublocade 1Ribavirin 1Radiotherapy 1Quinine 1Oxycodone 1Naloxone 1Ketamine 1Furosemide 1Filgrastim 1Fentanyl 1Escitalopram 1Donepezil 1Cyclophosphamide 1Buprenorphine, Naloxone Drug Combination 1Bimatoprost 1Artesunate 1Antilymphocyte Serum 1Amoxicillin-Potassium Clavulanate Combination 1Amlodipine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, Follicular × Buprenorphine, Naloxone Drug Combination × Clear all
NCT04091009 2025-12-31

Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms

Massachusetts General Hospital

Phase 4 Withdrawn
Lymphoid

Lymphoma, Follicular, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡